BJMO - volume 13, issue 3, may 2019
A. Bols MD, PhD, K. Geboes MD, PhD, M. De Man MD, T. Delaunoit MD, I. Sinapi MD, J. Carrasco MD, PhD, M. Peeters MD, PhD
SUMMARY
A retrospective study in patients treated with aflibercept plus FOLFIRI in second line for metastatic colorectal cancer (mCRC) was conducted in Belgium. A total of 102 patients (64.7% males; 62.9 ± 9.8 [mean ± SD] years-old; 36.3% Eastern Cooperative Oncology Group [ECOG] 0 and 63.7% ECOG 1 status) were included. At the end of the study, 47.1% of patients were deceased and 49% were still alive. The median overall survival (± SD) was 15.7 ±1.2 months (no statistically significant difference [p=0.706; log rank test] in survival as a function of the ECOG status). The median progression-free survival was 7.1 ±1.0 months (no statistically significant difference [p=0.732; log rank test] in progression-free survival as a function of the ECOG status). Aflibercept treatment was still ongoing in 22.5% of the patients. The treatment was stopped in 79 (77.5%) patients. In 16 patients (15.7%), treatment with aflibercept was discontinued due to drug toxicity. The average aflibercept treatment duration was 4.5 ± 4.5 months and the average number of aflibercept administrations was 8.7 ± 6.7. Overall, 62% of the patients having interrupted aflibercept received at least one targeted therapy or one chemotherapy after aflibercept. The three most frequent targeted therapies were regorafenib (46%), panitumumab (30%) and cetuximab (18%). The four most frequent chemotherapies were FOLFIRI (44.7%), FOLFOX (12.8%), irinotecan (12.8%) and capecitabine (12.8%). The results obtained using a retrospective observational real-life setting in Belgium globally corroborate those observed in the VELOUR randomised placebo-controlled trial.
(BELG J MED ONCOL 2019;13(3):98–104)
Read more
Top
